Table 4.
Comparisons of frequencies of ExRA and specific extra-articular manifestations according to the findings of positive or negative anti-CCP or anti-MCV.
| Characteristics | (−) RF n = 69 |
(+) RF n = 135 |
P | (−) anti-CCP n = 70 |
(+) anti-CCP n = 155 |
P | (−) anti-MCV n = 68 |
(+) anti-MCV n = 157 |
P |
|---|---|---|---|---|---|---|---|---|---|
| Presence of ExRA, n (%) | 30 (43.5) | 57 (42.2) | 0.86 | 27 (38.6) | 68 (43.9) | 0.46 | 26 (38.2) | 69 (43.9) | 0.43 |
| Specific manifestations | |||||||||
| Sjögren syndrome, n (%) | 23 (33.3) | 29 (21.5) | 0.07 | 18 (25.7) | 40 (25.8) | 1.00 | 16 (23.5) | 42 (26.8) | 0.61 |
| Chronic anemia, n (%) | 9 (13.0) | 23 (17.0) | 0.46 | 7 (10.0) | 26 (16.8) | 0.18 | 9 (13.2) | 24 (15.3) | 0.69 |
| Rheumatoid nodules, n (%) | 2 (2.9) | 19 (14.1) | 0.01 | 3 (4.3) | 20 (12.9) | 0.048 | 2 (2.9) | 21 (13.4) | 0.02 |
| P. neuropathy, n (%) | 6 (8.7) | 5 (3.7) | 0.19 | 5 (7.1) | 7 (4.5) | 0.52 | 4 (5.9) | 8 (5.1) | 0.76 |
The cut-off value to be considered anti-CCP as positive was ≥5 IU/mL, for anti-MCV, the levels considered as positive were ≥20 IU/mL. RA: rheumatoid arthritis; ExRA: extra-articular manifestations; anti-CCP: anti-cyclic citrullinated peptide antibodies; anti-MCV: anti-mutated citrullinated vimentin antibodies, P. neuropathy (peripheral neuropathy). Qualitative variables are expressed as frequencies (%). Comparisons between proportions were compared with Fisher exact test.